Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study

By sjmartinez • October 2, 2023

Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J, Sonni I. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 2;7(1):18. doi: 10.1186/s41824-023-00178-1. PMID: 37779132.

Tags: ADT, ARSi, Hematology/Oncology, PSMA-PET, Publications, RECIP, Veterans Administration

PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers

Gu Y, Ly A, Rodriguez S, Zhang H, Kim J, Mao Z, Sachdeva A, Zomorodian N, Pellegrini M, Li G, Liu S, Drakaki A, Rettig[...]

Alcohol and cannabis use associated with cardiometabolic biomarkers among “All of Us” cancer survivors

Arizpe A, Chapman TM, Rodriguez C, Carvajal A, Queen KJ, Navarro S, Ochoa-Dominguez CY, Kim SE, Toledo-Corral CM, Farias AJ. Alcohol and cannabis use associated[...]

Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment[...]